1,4-dimethyl-2-ethylimidazole | 53816-86-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1,4-dimethyl-2-ethylimidazole
• 英文别名: 2-Ethyl-1,4-dimethylimidazole
• CAS: 53816-86-7
• 化学式: C₇H₁₂N₂
• 分子量: 124.186
• InChiKey: GVQDVIAKPKRTFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-乙基-4-甲基咪唑 、 碘甲烷 在 18-冠醚-6 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 12.0h， 生成 1H-咪唑,2-乙基-1,5-二甲基-(9CI) 、 1,4-dimethyl-2-ethylimidazole
  参考文献：
  名称：

  Photo-, Solvent-, and Ion-Controlled Multichromism of Imidazolium-Substituted Diarylethenes

  摘要：

  AbstractSeeing red: Imidazolium‐substituted diarylethenes show solvent‐ and ion‐controlled chromisms in addition to reversible photochromic reactions. The shift of equilibrium between two closed‐ring isomers with different π‐conjugation length by interaction with nucleophilic species is responsible for the multichromic property (see scheme).magnified imageCationic diarylethenes with an imidazolium ring are synthesized for the first time. The imidazolium cationic moiety is connected directly to the ethene unit as one of the aryl units that take part in the photoinduced pericyclization reaction. The imidazolium‐substituted diarylethenes undergo reversible photochromic reactions in a variety of organic media, including ionic liquids, even though they have a delocalized cationic charge in one of the five‐membered aromatic rings. The closed‐ring isomer shows solvatochromism depending on the solvent donor numbers. Addition of some tetraalkylammonium salts, such as tetrabutyl ammonium nitrate, into the colored organic solution of diarylethene also causes a color change, indicating its ionochromic property. These solvato‐ and ionochromic properties are considered in connection with the shift of chemical equilibrium between the closed‐ring isomers, one with an extended π‐conjugation system and one with limited π‐conjugation due to the strong interaction with solvent molecules and anions with high donor number.

  DOI：

  10.1002/chem.200801192

文献信息

• 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
  申请人：GiraFpharma LLC

  公开号：US20190023702A1

  公开（公告）日：2019-01-24

  1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了作为腺苷受体调节剂的1,8-萘啶酮化合物。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。
• ELECTROLYTE SALT AND ELECTROLYTE FOR ELECTRICITY STORAGE DEVICE, AND ELECTRICITY STORAGE DEVICE
  申请人：NISSHINBO HOLDINGS INC.

  公开号：US20150291633A1

  公开（公告）日：2015-10-15

  Provided is an electrolyte salt comprising a quaternary ammonium cation indicated by formula (1) and a trimethylsilyl alkanesulfonate anion indicated by formula (2). (In the formula, R 1 -R 4 each independently indicate a C1-4 alkyl group or an alkoxyalkyl group indicated by —(CH 2 ) n —OR. Any two among R 1 -R 4 can mutually bond and form a ring together with a nitrogen atom to which same have bonded. The remaining two can mutually bond and form a spiro ring having a nitrogen atom as the spiro atom therefor. R indicates a methyl group or an ethyl group. n indicates 1 or 2 and m indicates 2 or 3.)

  提供的是一种电解质盐，包括由式（1）表示的季铵阳离子和由式（2）表示的三甲基硅烷烷磺酸盐阴离子。（在式中，R1-R4分别表示一个C1-4烷基或一个由—(CH2)n—OR表示的烷氧基烷基。R1-R4中的任意两个可以相互结合，并与它们结合的氮原子一起形成一个环。其余的两个可以相互结合，并形成一个以氮原子为螺旋原子的螺环。R表示一个甲基或一个乙基。n表示1或2，m表示2或3。）
• [EN] NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE<br/>[FR] NOUVEAUX INHIBITEURS DE KINASE PRÉSENTANT UNE ACTIVITÉ ANTICANCÉREUSE ET LEUR PROCÉDÉ D'UTILISATION
  申请人：ALLCRON PHARMA INC

  公开号：WO2019182944A1

  公开（公告）日：2019-09-26

  Pharmaceutical compositions of the invention comprise kinase inhibitors having a disease-modifying action in the treatment of diseases associated with BCR-ABL activity that include cancer, including chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, lymphomas, and metastatic carcinoma.

  本发明的药物组合物包括激酶抑制剂，在治疗与BCR-ABL活性相关的疾病中具有疾病修正作用，包括癌症，包括慢性髓细胞白血病、急性淋巴细胞白血病、急性髓细胞白血病、慢性淋巴细胞白血病、多发性骨髓瘤、淋巴瘤和转移性癌症。
• SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES
  申请人：Bayer Aktiengesellschaft

  公开号：US20200390100A1

  公开（公告）日：2020-12-17

  The present invention relates to substituted N-heterocyclyl- and N-heteroaryltetrahydropyrimidinones of the general formula (I) or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to the use thereof as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants.

  本发明涉及通式（I）或其盐的取代N-杂环烷基和N-杂芳基四氢嘧啶酮，其中通式（I）中的基团对应于描述中给出的定义，并将其用作除草剂，特别是用于控制作物中的阔叶杂草和/或杂草草，并/或作为植物生长调节剂，以影响作物的生长。
• Methods of Treating Obesity and Metabolic Disorders
  申请人：Hofgen Norbert

  公开号：US20090143392A1

  公开（公告）日：2009-06-04

  The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE10. The invention further relates to methods of reducing body fat or body weight.

  本发明涉及使用PDE10抑制剂pyrido [3,2-e] pyrazines治疗或预防肥胖症、2型糖尿病、代谢综合征或葡萄糖不耐症的方法。本发明还涉及减少体脂肪或体重的方法。